2024 |
Novartis AG - ADR
|
Chief Executive Officer |
14.2 M |
6.9 % |
2023 |
Novartis AG - ADR
|
Chief Executive Officer |
13.3 M |
21.1 % |
2022 |
Novartis AG - ADR
|
Chief Executive Officer |
11.0 M |
3.1 % |
2022 |
Novartis AG - ADR
|
- |
11.0 M |
3.1 % |
2021 |
Novartis AG - ADR
|
- |
10.6 M |
2.4 % |
2021 |
Novartis AG - ADR
|
Chief Executive Officer |
10.6 M |
2.4 % |
2021 |
Novartis AG - ADR
|
- |
10.6 M |
2.4 % |
2020 |
Novartis AG - ADR
|
- |
10.4 M |
-9.2 % |
2020 |
Novartis AG - ADR
|
Chief Executive Officer |
10.4 M |
-9.2 % |
2020 |
Novartis AG - ADR
|
- |
10.4 M |
-9.2 % |
2019 |
Novartis AG - ADR
|
- |
11.4 M |
15.3 % |
2019 |
Novartis AG - ADR
|
- |
11.4 M |
15.3 % |
2019 |
Novartis AG - ADR
|
Chief Executive Officer |
11.4 M |
15.3 % |
2018 |
Novartis AG - ADR
|
- |
9.9 M |
118.3 % |
2018 |
Novartis AG - ADR
|
- |
9.9 M |
118.3 % |
2018 |
Novartis AG - ADR
|
Chief Executive Officer |
9.9 M |
118.3 % |
2017 |
Novartis AG - ADR
|
- |
4.5 M |
27.8 % |
2017 |
Novartis AG - ADR
|
- |
4.5 M |
27.8 % |
2017 |
Novartis AG - ADR
|
Global Head, Drug Development and Chief Medical Officer, Novartis American |
4.5 M |
27.8 % |
2016 |
Novartis AG - ADR
|
- |
3.6 M |
- |
2016 |
Novartis AG - ADR
|
- |
3.6 M |
- |
2016 |
Novartis AG - ADR
|
Global Head of Drug Development and Chief Medical Officer for Novartis American |
3.6 M |
- |